Member Info for arsenal58

Gew
If what they expect too happen in the next three years, according to todays investor event.!!
Your valuations are very low
Around 58.5 billion divided by 586million = approx 98.67 pound a share lol
Boomtime

Usually sometimes
The breadth of Aviva, across life insurance and general insurance, is a key strategic advantage and has driven a 17% increase in operating profit4,5,‡ to £725 million. We also delivered some of our best ever sales figures in the first six months. In UK general insurance we delivered our highest sales3 in a decade. In Savings & Retirement, net flows‡ increased by 24% to a record £5.2 billion, and we've added 100,000 new workplace customers, reinforcing our number one position.

Alongside delivering growth, we continue to focus on reducing controllable costs4,6,‡ which are down 2%. We are on track to deliver our £300 million savings target in 2022 and are focused on achieving top quartile efficiency in all our businesses.

While we've got more to do, our half year results show we have what it takes to drive growth in our businesses. We remain completely focused on transforming performance, capitalising on the breadth of Aviva, making insurance simple and easy for our customers, and creating value for our shareholders."

Return of capital to shareholders of at least £4bn by HY 2022 with full details with FY results in March 20221
They seem to think they have beat previous operating profit??

the investor event is 2pm BST aiming for a US audience!!

If a bid is in the wings it will be soon,before the large appreciation AV. will acquire
Five pound plus on next upward movement seems a fair prediction!!

Numbers shame about the divi
Seem to be holding has much cash as possible saying its for M&A???
IMO. Positioning thereselves for the blockbusting bid that cannot be far away ??

Rock/
Spike
How much to buy AV.
700 to 750 pence
Around seven billion in cash
Number one in its territories
Pe ratio only five point five (approx)
Divi yield six point five percent (approx)
This share is so undervalued
Surely a takeover target for a American bank or insurer ??

You are a little touchy !!
I remember this share being 550 and above
With your remarks you just showed your a novice at the game
Good luck tomorrow everybody else
Ps they will have made lots of money from the M&A this year although some will not be recorded yet

Big buyback, big divi,big special,and 550 per share
Boomtime lol

GS
PANR sound a little desperate with the phrasing in that RNS !!
I sold this am. sit and wait too see what happens on the funding front
GLA

Punter
We are worth more now for them in many ways
Land and property in Malaysia they would live to get their hands on
Plus Indonesia openings are young and ripe for large expansion
They still hold a large stack of shares also
All in good time as per usual

28 July 2021SPORTECH PLC("Sportech", the "Group" or the "Company") Admission of Ordinary Shares to trading on AIM Sportech (AIM:SPO), an international betting technology business, announces that further to the Company's announcement on 4 June 2021, the General Meeting held on 29 June 2021 and the Schedule 1 and Schedule 1 Appendix announcements made on 30 June 2021, the Board is pleased to confirm that the admission of the Company's ordinary shares of 20 pence each (the "Ordinary Shares") to trading on AIM occurred at 08.00 a.m. today, 28 July 2021. Simultaneously, the admission of the Company's Ordinary Shares on the Official List of the Financial Conduct Authority and to trading on the Main Market of London Stock Exchange plc has been cancelled. The Ordinary Shares will continue to trade under the TIDM "SPO", the LEI and ISIN will also remain the same. Company information, as required by AIM Rule 26, can be found at http://www.sportechplc.com. - Ends -

Upwardly mobile company this is
Come on KLK!! 15 pound and we are yours ??

Why are you thinking about the divi if you have sold out ???

Was a structured sell ??

Oversubscribed ipo

Offer ahoy

Over 23.08 is a buy people
Not sells has documented

Outlined within its quarterly report, Pfizer cited key data from the hVIVO-sponsored human challenge trial, which involved testing a vaccine candidate of respiratory syncytial virus (RSV).

Furthermore, results from the study yielded 100% efficacy against symptomatic disease in 18- to 50-year-olds.

(Source: Pfizer)

Results from Phase 2, which is to be submitted for peer-reviewed publication soon, show the vaccine was 100% effective against mild-to-moderate symptomatic infection. The Group highlighted that most participants in the study experienced minimal to no side effects.

Meanwhile, as a performance benchmark, the Ad26.RSV preF vaccine showed 52% observed efficacy in the same human challenge model, the company outlined to investors.

In Pfizer's 2Q21 earnings conference call which occurred last Wednesday, Mikael Dolsten, President of Worldwide Research and Development and Medical noted that there remains much excitement about the trial’s data as well as the opportunity for an RSV adult vaccine.

Addressing Pfizer shareholders, he commented: “There are hundreds of thousands of cases, and they -- per year in the US, and they are particular, of course, difficult for -- in older adults above 60 or adults that have underlying conditions, whether chronic lung diseases or immunocompromised. Now, there are actually up to 15,000 deaths just in the US annually.”

Going forward, Phase 3 of the human challenge study which will be focused on RSV in adults is expected to commence in 3Q21 with a potential conclusion expected as early as 1Q22.

View from VOX

hVIVO is proving to be a world class asset for ORPH.

In addition to being selected by Pfizer for RSV as outlined above, it was recently chosen to work alongside the UK Government earlier this year as part of the of the characterisation study where researchers would aim to identify a dose of the COVID-19 virus that causes a safe and reliable infection in unvaccinated COVID-19 naïve volunteers. Last month, the UK Government said it had decided to expand the Human Challenge Programme to answer further questions that can help in the fight against COVID-19.

The study, which is being conducted by hVIVO at the Royal Free Hospital and funded by the UK Government who have commissioned Imperial College London as the study sponsor, will initiate as soon as appropriate regulatory approvals and clinical preparations are complete.

The Group said existing data from the characterisation study has already provided valuable insight into the biology of the virus which causes COVID-19 while further data is expected to improve the ability to manage the virus and deliver a range of treatment options in the future.?

Also commenting on ORPH’s outlook, analysts at research firm Arden Partners said the group’s pipeline is ‘continuing to grow through interactions with key global pharma players with signed deals in 2021 already ahead of 2020, underpinning confidence in the outlook.’?

Op

Contract win with unnamed new customer

Back in August 2020,
Open Orphan
(ORPH
Follow
) secured a €4m contract to trial a new treatment for respiratory syncytial virus, which causes infections of the lungs and respiratory tract.

Addressing shareholders at the time, Open Orphan’s Chairman, Cathal Friel said: “This is another exciting new contract win with a new [and unnamed] customer for Open Orphan’s subsidiary hVivo as we convert the substantial pipeline that is building up within the company.”

RSV, a contagious virus that affects children and at-risk older adults, is considered a significant public health threat and a leading cause of hospitalisation of young children globally. In severe cases, it can cause pneumonia and life-threatening breathing difficulties.

‘RSV may also lower immunity and increase the risk of developing COVID-19, and where these infections occur together, it can worsen the severity of COVID-19 illness,’ the Company also explained at the time.

hVivo, which holds a quarantine facility in Whitechapel, is a clinical trial business that can accelerate drug and vaccine development, specialising in human challenge studies. The RSV trial forms part of Open Orphan’s wider expansion from one clinic to multiple clinics.

“hVIVO is currently the only company worldwide that can facilitate RSV challenge studies and we are in advanced negotiations with all the significant RSV vaccine and drug developers globally. Our multiple state-of-the-art East London quarantine facilities are well equipped to carry out this study in a safe and controlled clinical environment,” said Friel.

In a research note released in March 2021, analysts at Arden Partners commented: “There is currently no specific treatment on the market for RSV and Open says hVIVO division is “currently the only company worldwide” that can facilitate challenge studies for the virus.”

As a result, Open Orphan described the contract as ‘substantial and significant’ and said it is in advanced negotiations with all the significant RSV vaccine and drug developers globally.? There are no existing effective licensed therapies generally available for RSV disease.

Pfizer announces RSV results during 2Q20 earnings call

Further analysis during an Q2 2021 earnings call

Pfizer last week cited the “successful” Phase 2a human challenge trial as a key highlight within its 2Q21 results.

Importantly for ORPH investors, Pfizer highlighted the RSV Adult Vaccine as part of its “First in Class Science Update

ScweeAferian PLC - Cambridge, England-based media technology company - Acquires the remaining 8% minority interest in 24i Unit Media BV and its subsidiaries. The amount due to the founders of 24i is EUR3.3 million, which is the same price paid per share as for the 92% shareholding acquired in July 2019. It is anticipated that the company will pay cash of EUR1.0 million, with the remaining EUR2.3 million to be settled through the issue of shares.Separately, the company reports double digit growth in both revenue and annual recurring revenue for the six months to May 31, up 19% to USD45.3 million and up 37% to USD13.8 million, respectively. Pretax profit tripled to USD1.5 million from USD500,000 year-on-year. Aferian declares dividend of 1.0 pence a share.Current stock price: 151.00pYear-to-date change: up 26%This report is not has pessimistic has your remarks??